Wednesday, July 12, 2017 7:17:11 AM
"Polyurethane’s strength is also its weakness: it gets soft, at body temperature, very quickly. This works well when access is fast—when the vessel is shallow and easily cannulated. However, when the vessel is deep, rolling or sclerotic and time is required to ultimately access it, then the polyurethane catheter softens before it is advanced off the needle; when this happens, and it happens often with UGPIVs, the tip of the catheter crumples as it encounters the vessel wall and will not advance. This is why UGPIV has a good “success” rate, but generally not a good “first-attempt success” rate.10
What is clearly needed is a longer catheter, made of a new material (Chronoflex C) that will soften in time, but not as quickly as polyurethane. Clinicians need an extra minute or two to cannulate the deeper more elusive vessels of DIVAs.
Presently, there is but one entry into the emerging EDC marketplace, as defined above. It is a 6cm, 3Fr (19.5g), power-injectable, non-trimmable IV catheter made of a unique polymer and FDA cleared for insertion “in the vascular system” for up to 29 days. This first EDC, despite encouraging early reports, has yet to demonstrate evidence of performance in a peer-reviewed journal. One hopes such evidence will surface quickly."
http://www.infectioncontroltoday.com/articles/2017/07/a-new-tool-for-the-vascular-access-toolbox.aspx
"POWERWAND EDC is a whole new class of Vascular Access Device (VAD). POWERWAND EDC is the only power injectable 3Fr, 6cm (2.4”) extended dwell catheter on the market"
http://accessscientific.com/edc/
Here's hoping it's selling
Recent NORD News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/06/2024 07:02:29 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 12/15/2023 05:15:19 AM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 12/06/2023 08:46:07 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 11/27/2023 10:16:50 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM